CRISPR Correction of Duchenne Muscular Dystrophy
Summary
The ability to efficiently modify the genome using CRISPR technology has rapidly revolutionized biology and genetics and will soon transform medicine. Duchenne muscular dystrophy (DMD) represents one of the first monogenic disorders that has been investigated with respect to CRISPR-mediated correction of causal genetic mutations. DMD results from mutations in the gene encoding dystrophin, a scaffolding protein that maintains the integrity of striated muscles. Thousands of different dystrophin mutations have been identified in DMD patients, who suffer from a loss of ambulation followed by respiratory insufficiency, heart failure, and death by the third decade of life. Using CRISPR to bypass DMD mutations, dystrophin expression has been efficiently restored in human cells and mouse models of DMD. Here, we review recent progress toward the development of possible CRISPR therapies for DMD and highlight opportunities and potential obstacles in attaining this goal.
| Authors | Min YL, Bassel-Duby R, Olson EN |
|---|---|
| Journal | Annual review of medicine |
| Publication Date | 2019 Jan 27;70:239-255 |
| PubMed | 30379597 |
| PubMed Central | PMC6415693 |
| DOI | 10.1146/annurev-med-081117-010451 |